These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 343957)

  • 21. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis.
    Nobels F; Dewailly D
    Fertil Steril; 1992 Oct; 58(4):655-66. PubMed ID: 1426306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiological aspects of the steroid hormone-gonadotropin interrelationship.
    Grant-Brown K
    Int Rev Physiol; 1977; 13():57-83. PubMed ID: 321384
    [No Abstract]   [Full Text] [Related]  

  • 23. Polycystic ovary syndrome: androgens and hypertension.
    Reckelhoff JF
    Hypertension; 2007 Jun; 49(6):1220-1. PubMed ID: 17389256
    [No Abstract]   [Full Text] [Related]  

  • 24. Polycystic ovary syndrome/hyperandrogenic chronic anovulation.
    Lobo RA
    Adv Endocrinol Metab; 1995; 6():167-91. PubMed ID: 7671095
    [No Abstract]   [Full Text] [Related]  

  • 25. [Polycystic ovary syndrome (author's transl)].
    Lecomte P; Kuttenn F; Mauvais-Jarvis P
    Nouv Presse Med; 1978 Feb; 7(5):355-6, 361-2. PubMed ID: 345233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. British Fertility Society. 'Ovulation induction in WHO Type 1 anovulation: Guidelines for practice'. Produced on behalf of the BFS Policy and Practice Committee.
    Yasmin E; Davies M; Conway G; Balen AH; British Fertility Society
    Hum Fertil (Camb); 2013 Dec; 16(4):228-34. PubMed ID: 24245485
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment with pulsatile luteinizing hormone-releasing hormone modulates folliculogenesis in response to ovarian stimulation with exogenous gonadotropins in patients with polycystic ovaries.
    Homburg R; Kilborn J; West C; Jacobs HS
    Fertil Steril; 1990 Oct; 54(4):737-9. PubMed ID: 2120089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.
    Barnes RB
    J Endocrinol Invest; 1998 Oct; 21(9):567-79. PubMed ID: 9856411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Filicori M; Flamigni C; Campaniello E; Meriggiola MC; Michelacci L; Valdiserri A; Ferrari P
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 2):1737-42. PubMed ID: 2122730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evaluation and treatment of androgen excess.
    Practice Committee of the American Society for Reproductive Medicine
    Fertil Steril; 2006 Nov; 86(5 Suppl 1):S241-7. PubMed ID: 17055833
    [No Abstract]   [Full Text] [Related]  

  • 31. Hormonal therapy in ovarian cancer.
    Zheng H; Kavanagh JJ; Hu W; Liao Q; Fu S
    Int J Gynecol Cancer; 2007; 17(2):325-38. PubMed ID: 17362310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP; Lu JK; Chang RJ
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gonadotropin regulation, oestrogens and the immune system.
    Kordon C; Drouva SV
    Horm Res; 1992; 37 Suppl 3():11-5. PubMed ID: 1427636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The steroid hormone metabolism in the human ovary].
    Lisse K; Schürenkämper P
    Zentralbl Gynakol; 1968 Mar; 90(12):401-8. PubMed ID: 5710025
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperandrogenemia: pathophysiology and its role in ovulatory dysfunction in PCOS.
    Diamanti-Kandarakis E; Papailiou J; Palimeri S
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():198-204. PubMed ID: 16641860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycystic ovary syndrome.
    Norman RJ; Dewailly D; Legro RS; Hickey TE
    Lancet; 2007 Aug; 370(9588):685-97. PubMed ID: 17720020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity and the polycystic ovary syndrome.
    Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
    Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovulation induction with pulsatile gonadotropin-releasing hormone administration in patients with polycystic ovarian syndrome.
    Ory SJ; London SN; Tyrey L; Hammond CB
    Fertil Steril; 1985 Jan; 43(1):20-5. PubMed ID: 3880710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of GnRH drive in the pathophysiology of polycystic ovary syndrome.
    Leondires MP; Berga SL
    J Endocrinol Invest; 1998; 21(7):476-85. PubMed ID: 9766266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.